Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Real-world data on the efficacy of CAR-T therapy in patients with ALL

In this video, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses real-world data (RWD) collected from a large series of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) that received CAR-T cell therapy, which confirmed the efficacy, safety, and response rates of this therapy. Prof. Mohty also highlights that further research is needed to determine whether patients receiving CAR-T therapy also require allogeneic stem cell transplantation (alloSCT). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Astellas: Honoraria; GSK: Honoraria; Pfizer,: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Oncopeptides: Honoraria; Adaptive Biotechnologies: Honoraria; Amgen: Honoraria; Bristol Myers Squibb: Honoraria; Celgene: Honoraria; Jazz Pharmaceuticals: Honoraria, Research Funding; Gilead: Honoraria; Sanofi: Honoraria, Research Funding; Janssen: Honoraria, Research Funding.